Daphne Koller, insitro CEO (Stefan Wermuth/Bloomberg via Getty Images)
December 18, 2024 07:00 AM EST
R&D
AI

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Andrew Dunn

Senior Biopharma Correspondent

The AI-fo­cused biotech in­sitro is ad­vanc­ing a new idea to po­ten­tial­ly treat ALS, one of the most in­tractable and bru­tal dis­eases.

The South San Fran­cis­co …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

A service from the Financial Times